rMeV-MG53

rMeV-MG53 is an engineered oncolytic measles virus (MeV) based on the attenuated Edmonston vaccine strain, designed to express the tripartite motif-containing protein 72 (TRIM72), also known as Mitsugumin 53 (MG53). This therapeutic agent leverages the natural tumor-selectivity of the measles virus, which preferentially replicates in malignant cells overexpressing CD46. Beyond direct viral oncolysis, rMeV-MG53 is specifically designed to induce caspase-3/GSDME-mediated pyroptosis, a highly inflammatory form of programmed cell death. This process releases damage-associated molecular patterns (DAMPs) and inflammatory cytokines, thereby priming the immune system against tumor antigens. Preclinical data in lung cancer models demonstrate that rMeV-MG53 significantly inhibits tumor growth and acts synergistically with immune checkpoint inhibitors, such as anti-PD-L1 antibodies, to enhance antitumor efficacy.

Other names

recombinant measles virus expressing MG53MeV-MG53MeV-MG-53MeV-MG 53